![](/static/index/imgs/tc2-1.png)
发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
INTRODUCTION:To assess treatment outcome and prognostic factors associated with prolonged survival in patients with brain metastases (BM) treated with stereotactic radiosurgery (SRS) or hypofractionated stereotactic radiotherapy (HFSRT). METHODS/PATIENTS:This study retrospectively reviewed 200 patients with 324 BM treated with one fraction (15-21 Gy) or 5-10 fractions (25-40 Gy) between January 2010 and August 2016. 26.5% of patients received whole brain radiotherapy (WBRT) and 25% initial surgery. Demographics, prognostic scales, systemic and local controls, patterns of relapse and rescue, toxicity, and cause of death were analyzed. A stratified analysis by primary tumor was done. RESULTS:Median overall survival (OS) was 8 months from SRS/HFSRT. Breast cancer patients had a median OS of 17 months, followed by renal (11 months), lung (8 months), colorectal (5 months), and melanoma (4 months). The univariate analysis showed improved OS in females (p 0.004), RPA I-II (p < 0.001) initial surgery (p < 0.001), absence of extracranial disease (p 0.023), and good disease control (p 0.002). There were no differences in OS or local control between SRS and HFSRT or in patients receiving WBRT. Among 44% of brain recurrences, 11% were in field. 174 patients died, 10% from confirmed intracranial progression. CONCLUSIONS:SRS and HSFRT are equally effective and safe for the treatment of BM, with no exceptions among different primary tumors. Disease control, surgery, age, and prognostic scales correlated with OS. However, the lack of survival benefit regarding WBRT might become logical evidence for its omission in a subset of patients.
展开更多
最新影响因子:3.34 | 期刊ISSN:1699-048X | CiteScore:5.16 |
出版周期:Monthly | 是否OA:YES | 出版年份:2005 |
自引率:2.20% | 研究方向:医学-肿瘤学 |
出版地区:SPAIN |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of biomarkers for cancer diagnosis, prognosis or prediction of treatment response, identification of new targets for cancer therapy, as well as development of new technologies for research and treatment of cancer are the major themes covered by both the educational series and research articles. A broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.
《临床与转化肿瘤学》是一本致力于促进实验肿瘤学与临床肿瘤学相互作用的国际期刊。它涵盖了癌症研究的所有方面,从涉及肿瘤细胞和分子生物学的更基本的发现,到最先进的传统和新药的临床检测。此外,该杂志致力于促进从基础实验室到临床实践的知识转移,出版了一系列致力于缩小分子肿瘤学家和临床肿瘤学家之间差距的教育系列。肿瘤分子生物学、癌症诊断生物标记物的识别、治疗反应的预后或预测、癌症治疗新靶点的识别以及癌症研究和治疗新技术的开发是教育系列和研究文章的主题。将考虑发表广泛的主题,包括疾病的分子和细胞基础、病因学、病理生理学、病理学、流行病学、临床特征以及癌症的诊断、预后和治疗。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
ONCOLOGY (肿瘤学) 4区 |
156/223 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
179 | 144 | 35 |
引文计数(2018)
文献(2015-2017)
8579次引用
1661篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Pulmonary and Respiratory Medicine
|
#4/132
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
15年经验沉淀,实体公司
运营
liting7111
研究方向:肿瘤 癌症
审稿时间: 2个月内
liting7111
研究方向:肿瘤 癌症
liting7111
研究方向:肿瘤 癌症
审稿时间: 2个月内 接受率: 中等(50%命中)
liting7111
liting7111
研究方向:meta
审稿时间: 2个月内 接受率: 比较困难(25%命中)
liting7111
审稿时间: 2个月内 接受率: 中等(50%命中)
影响因子:13.029
ISSN:1522-8517
研究方向:医学-临床神经学
影响因子:4.506
ISSN:0167-594X
研究方向:医学-临床神经学
影响因子:7.723
ISSN:2162-402X
研究方向:ONCOLOGYIMMUNOLOGY-IMMUNOLOGY
影响因子:4.912
ISSN:1524-9557
研究方向:医学-免疫学
影响因子:12.02
ISSN:2326-6066
研究方向:ONCOLOGY-IMMUNOLOGY
影响因子:3.698
ISSN:1750-9378
研究方向:ONCOLOGY-IMMUNOLOGY
影响因子:6.63
ISSN:0340-7004
研究方向:医学-免疫学
影响因子:3.077
ISSN:1534-7354
研究方向:医学-全科医学与补充医学
影响因子:0
ISSN:1868-8497
研究方向:ONCOLOGY-ENDOCRINOLOGY & METABOLISM
专注医学期刊服务15年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
Clinical & Translational Oncology 投稿经验
(由下方点评分析获得,6人参与,37066人阅读)